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Abstract
Introduction—Nearly a decade ago, researchers identified a potential interaction between
tamoxifen and strong CYP2D6 inhibitors, including several frequently used antidepressants.
Based on evidence available at that time, a United States Food and Drug Administration advisory
committee recommended tamoxifen’s label be changed in October 2006, noting that
postmenopausal women with estrogen receptor-positive breast cancer who are poor CYP2D6
metabolizers by genotype or drug interactions may be at increased risk of cancer recurrence. The
impact of accumulating drug risk information on antidepressant use is unknown.
Methods—Retrospective, longitudinal cohort study of 13,205 women aged 50–95 with breast
cancer initiating tamoxifen between July 2004–December 2009. We evaluate trends in strong,
moderate, and weak CYP2D6-inhibitor antidepressants and tamoxifen co-prescribing and factors
associated with ongoing strong inhibitor use. A propensity-score matched control group
(aromatase inhibitor initiators) was used to estimate changes in co-prescribing, accounting for
secular trends.
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Results—In each month, approximately 24% of tamoxifen and aromatase inhibitor users were
prescribed antidepressants. Among women using tamoxifen and antidepressants, 34% used strong
inhibitors between 2004 and 2006 versus 15% in 2010. Strong inhibitor use decreased more
among tamoxifen users than aromatase inhibitor users (Difference-in-Differences, [DD]: −0.09,
95% Confidence Interval, [CI]: −0.15, −0.03). Weak inhibitor use increased among tamoxifen
users from 32% between 2004 and 2006 to 52% in 2010, more rapidly than among aromatase
inhibitor users (DD:0.15, CI:0.08, 0.23). The factor most strongly associated with strong inhibitor
and tamoxifen co-prescribing after 2006 was prior strong inhibitor use (RR:4.73, CI:3.62–6.18).
Conclusion—There were substantial declines in strong CYP2D6-inhibitor use among tamoxifen
users following dissemination of information suggesting a potential for increased risk with co-
prescribing. Whether patients and providers will continue to avoid strong inhibitor antidepressants
is yet to be seen, but clinicians appear to be responsive to drug interaction risk information in this
setting.
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INTRODUCTION
An estimated 230,480 women were diagnosed with breast cancer in the U.S. in 2011, and
approximately two-thirds of these cancers were hormone (estrogen and/or progesterone)
receptor-positive [1–4]. For women with hormone receptor-positive breast cancers, adjuvant
endocrine therapy with tamoxifen or aromatase inhibitors substantially decreases the risk of
cancer recurrence [5]. Current guidelines recommend treatment with tamoxifen and/or an
aromatase inhibitor for 5 years for postmenopausal women with hormone receptor-positive
early-stage breast cancer [7, 8].
Over the last decade researchers have been investigating a potential link between CYP2D6
inhibition and breast cancer recurrence among women taking tamoxifen [9, 10]. Several
studies over that timeframe have suggested that certain antidepressants inhibit the
metabolism of tamoxifen, theoretically reducing tamoxifen’s effectiveness and thereby
increasing the risk of breast cancer recurrence [11–15]. In response to concerns about
CYP2D6 inhibition, in October 2006 a Food and Drug Administration (FDA) advisory
committee recommended tamoxifen’s label be changed, noting that postmenopausal women
with ER-positive breast cancer who are poor CYP2D6 metabolizers by genotype or due to
drug interactions may be at increased risk of cancer recurrence.
Subsequent evidence of the impact of concurrent antidepressant and tamoxifen use on
patient outcomes has been mixed [11, 17–20], including two large, recently published
studies that suggest that CYP2D6 metabolism is not associated with breast cancer outcomes.
[18, 19] Nevertheless, as researchers have worked to identify the role of CYP2D6
metabolism on outcomes among patients taking tamoxifen clinical guidelines and
publications developed over recent years have generally encouraged the avoidance of strong
inhibitors among tamoxifen users [21–24] given the number of treatment alternatives
available [11, 24–26]. Since antidepressants are frequently used for treating depression,
anxiety, and hot flashes among women with breast cancer, [26–29] understanding the impact
of accumulating drug risk information on overall antidepressant use is important.
Our objectives were to examine trends in overall antidepressant-tamoxifen co-prescribing
over time, with a focus on changes following the October 2006 FDA advisory meeting. We
also assessed changes in co-prescribing for strong, moderate, and weak CYP2D6 inhibitors
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and evaluated patient and treatment characteristics associated with use of strong CYP2D6
inhibitors following the advisory committee meeting.
METHODS
Data Source
We used data from the Thompson Reuters MarketScan Commercial Claims and Encounters
and Medicare Supplement databases for calendar years 2004–2010. Together these data
represent the healthcare experience of retired and non-retired employees and their
dependents enrolled in commercial health insurance plans sponsored by over 100 large or
medium sized U.S.-based employers. The data include monthly enrollment data, inpatient
and outpatient medical claims, and outpatient prescription drug claims. The Medicare
Supplemental database includes Medicare beneficiaries with employer-sponsored
supplemental insurance from a MarketScan employer. In 2007, over half of all Medicare
beneficiaries with incomes over $30,000 received employer-sponsored supplemental
coverage [30]. Overall, the MarketScan data represent over 50 million enrollees and is the
largest convenience sample available in proprietary U.S. claims databases [31].
Design and Study Populations
We assessed changes in co-prescribing of antidepressants among women taking tamoxifen
before and after the FDA advisory committee meeting compared with women taking
aromatase inhibitors (adjuvant endocrine therapy for which there are no concerns about
interactions with CYP2D6 inhibitors). We identified women aged 50 years or older with two
or more diagnoses for breast cancer (ICD-9 codes 174.x, at least 30 days apart) during
2004–2010 who had prescription drug coverage data reported to MarketScan. Among these
women, we identified women with a first prescription for tamoxifen or an aromatase
inhibitor (anastrozole, exemestane, or letrozole) between July 1, 2004 and December 31,
2009. The first observed dispensing date for an endocrine therapy was considered the index
drug date. Women without at least 6 months of continuous enrollment before their index
drug date were excluded, as were women with other cancer diagnoses (ICD-9 codes 140–
208.81, except 174.x [breast cancer], 173.x [non-melanoma skin cancers], and 196–199.1
[metastatic cancer]), those who did not have a breast cancer diagnosis from 6 months before
through 1 year after the index date and those who switched from tamoxifen to aromatase
inhibitors (or vice versa) within the index year. This resulted in 52,612 women eligible for
analyses.
Ascertainment of Medication Use
Pharmacy claims were used to assess monthly utilization of tamoxifen, aromatase inhibitors
and antidepressants. Each woman was considered a medication user in a month if they had
at least 15 days of medication available during the month. Available medication was
calculated using the fill date and days of supply.
We classified antidepressants by their cytochrome p450 inhibitor status based on the most
recent guidelines from the American Psychiatric Association [22]. We considered
bupropion, fluoxetine and paroxetine to be strong inhibitors; desipramine, duloxetine,
escitalopram, norfluoxetine and sertraline to be moderate inhibitors; and citalopram,
imipramine, nortriptyline, selegiline, desmethylsertraline and venlafaxine to be weak
inhibitors.
Covariates
We adjusted for the following control variables measured in the month of the patient’s index
endocrine therapy: patient age, insurance type (commercial or Medicare), region, and the
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enrollees’ relationship to employee (employee or spouse) and quarter during which the
endocrine therapy was prescribed. We used administrative data to characterize other
diagnoses and health care utilization in the 6 months preceding the index prescription fill
date. We assessed antidepressant need by identifying diagnoses of major depressive disorder
(ICD-9 codes: 296.2, 296.3), other depression diagnoses (ICD-9 codes: 300.4x, 311.x), and
anxiety disorder (ICD-9 codes: 293.84, 300.0x, 300.2x, 300.3, 308.3, 309.21, 309.81). We
documented hospitalizations with a breast cancer diagnosis code and inpatient or outpatient
diagnosis codes for metastatic breast cancer (ICD-9 codes: 196.x–199.1), and we
characterized comorbidity using the Klabunde modification of the Charlson score [32]. We
characterized health service utilization using measures of the number of medication classes
[33, 34](excluding antineoplastic and psychotherapeutic agents), the number of outpatient
visits, receipt of treatment from a psychiatrist, and care by primary care physicians and
oncologists, categorized as primary care physicians only, oncologists only, or both primary
care physicians and oncologists. We adjusted for differences in antidepressant need and
health care services use over time by controlling for depression diagnoses, prior
antidepressant use (separate indicators for strong, moderate or weak inhibitors) and
frequency of outpatient visits during the 6-month period preceding each endocrine fill.
Propensity Score Match
We created a propensity-score matched cohort in which patients initiating treatment with
tamoxifen were matched to those initiating treatment with aromatase inhibitors [35]. Using
women taking aromatase inhibitors as the control group allowed us to estimate changes in
co-prescribing among tamoxifen users while controlling for changes in antidepressant use
over the study period in a group of patients that would not be subjected to the same drug
interaction risk concerns (i.e., aromatase inhibitors are not metabolized via the CYP2D6
pathway). To perform the propensity score match, we modeled the probability of receiving
tamoxifen (vs. aromatase inhibitor) as a function of all of the pre-treatment covariates
described above, with separate matching within calendar year to account for changes in
adoption of endocrine therapy and interactions between covariates and time. Next, using the
resulting propensity score, we matched patients initiating treatment with tamoxifen 1:1 to
those initiating treatment with aromatase inhibitors.
Analytic Strategy
Using the propensity score matched cohort, we estimated multivariate adjusted changes in
the proportion of women receiving an antidepressant for each person-month of endocrine
therapy use. Next, we estimated changes in the use of strong, moderate and weak CYP2D6
inhibitors among antidepressant users for each person-month, thus the unit of analysis was
the medication-fill. We used generalized estimating equations with a log link and Poisson
distribution to control for repeated observations on individuals over time. Women were
allowed to contribute up to 12 months of person-time to the analysis. For each outcome we
compared average monthly prescribing before the FDA advisory committee meeting (from
October 2004–October 2006) to prescribing in each subsequent year (from November 2006–
October 2010). To isolate changes in antidepressant use among tamoxifen users that were
due to concerns about CYP2D6 interaction risk, and not antidepressant market changes
alone, we implemented a difference-in-differences modeling approach. We used SAS 9.2
(Cary, NC) for analyses.
Finally, we modeled patient and treatment characteristics related to use of strong inhibitors
following the FDA advisory committee meeting. We restricted these analyses to women
using tamoxifen and an antidepressant in the post-advisory period. Comparisons were
between those co-prescribed strong inhibitors and those co-prescribed moderate, weak or
unclassified inhibitors.
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To test the robustness of our study findings to the timeframe selected, we revised the
timeframe to consider (1) an aggregate post-advisory period (from November 2006–October
2010), and (2) shorter and longer-term changes in co-prescribing by estimating use in the
first year post-advisory period (from November 2006–October2007) separately from the
remaining post-advisory period.
Second, we restricted our sample to women who had continuous enrollment for the 12-
month period following their index prescription-fill to determine whether differences in
follow-up might bias our estimates. Third, to account for delays in transitioning patients
from strong inhibitors we also assessed patient and treatment characteristics of individuals
receiving strong inhibitors two years or more following the advisory (from November 2008–
October 2010). Finally, we excluded 16% of the patients in our sample who received
carved-out mental health services since our ability to detect mental health diagnoses (but not
prescriptions) may be limited for these individuals.
RESULTS
Patient Characteristics
Before matching, women receiving tamoxifen as their index treatment differed from women
receiving aromatase inhibitors (Table 1). Women receiving tamoxifen were younger, less
likely to be treated for cancer in an inpatient setting or to have metastatic breast cancer
diagnoses, and had fewer outpatient visits and classes of medications prescribed in the 6
months before the index prescription date. We successfully matched 13,205 of 14,346
tamoxifen users to an aromatase inhibitor user. After matching, the two groups were well
balanced on all baseline characteristics. Tamoxifen users who were unmatched
(approximately 8% of the sample) were younger, but otherwise similar, to those in the
matched cohort.
Endocrine Therapy and Antidepressant Co-Prescribing
Approximately 24% of women using either tamoxifen or aromatase inhibitors in any given
month also received a prescription for an antidepressant within that same month. Co-
prescribing of antidepressant therapies remained constant over the study period among
women taking tamoxifen and women taking aromatase inhibitors (Figure 1).
Strong Inhibitor Co-Prescribing
For women taking both tamoxifen and antidepressants, 34% were prescribed strong
inhibitors during the first two years of observation (Figure 2). Strong inhibitor use decreased
among all endocrine therapy users following the FDA advisory committee meeting in
October 2006. However, comparing use between the two groups, co-prescribing decreased
more among tamoxifen users than aromatase inhibitor users from the pre-advisory period to
the most recent year (Difference-in-Differences [DD]: −0.09, 95% Confidence Interval[CI]:
−0.15, −0.03) (Table 2). By 2010, strong inhibitors were used in approximately 15% of
women co-prescribed tamoxifen and antidepressants versus 24% of women co-prescribed
aromatase inhibitors and antidepressants.
Moderate Inhibitor Co-Prescribing
Use of moderate CYP2D6 inhibitors increased somewhat among all endocrine therapy users
during the first two years following the FDA advisory committee meeting. Use among
women taking tamoxifen returned to pre-advisory levels in the third and fourth year
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following the advisory. There were no statistically significant differences in moderate
inhibitor use over time between tamoxifen users and aromatase inhibitor users (Table 2).
Weak Inhibitor Co-Prescribing
Use of weak CYP2D6 inhibitors increased significantly among tamoxifen users following
the FDA advisory committee meeting. For women taking tamoxifen, weak inhibitors made
up 32% of antidepressant fills before the FDA advisory, and 52% by 2010. From the pre-
advisory period to the most recent year, weak inhibitor use grew more among tamoxifen
users than aromatase inhibitor users (DD:0.15, CI:0.08, 0.23, Table 2).
Characteristics Associated with Strong Inhibitor Use
Several characteristics were associated with co-prescribing of strong inhibitors and
tamoxifen following the FDA advisory committee meeting (Table 3). Women using strong
inhibitors before the advisory were more likely to use strong inhibitors after the advisory
period, compared with women using moderate, weak or unclassified inhibitors (RR:4.73, CI:
3.62, 6.18). The year during which tamoxifen treatment was initiated was also associated
with strong inhibitor use, with individuals initiating tamoxifen prior to 2009 being more
likely to receive strong inhibitors. Finally, having more comorbid conditions (measured
using the Klabunde modification of the Charlson index) and having a higher than average
number of outpatient visits were associated with a greater likelihood of strong inhibitor use.
Sensitivity Analyses
Results of sensitivity analyses using alternative definitions of the post-advisory periods and
those restricted to women with 12 months of continuous enrollment were consistent with the
primary analysis. Similarly, for modeling patient and provider characteristics associated
with post-advisory strong inhibitor use, results from our primary analysis were identical to
those restricted to patients using strong inhibitors during 2009 and 2010. Finally, there were
no differences in our primary analysis results and models excluding individuals with
possible missing mental health services data.
CONCLUSIONS
Among women with breast cancer initiating tamoxifen therapy, we found significant
reductions in strong CYP2D6 inhibitor use following reports of potential drug-drug
interactions. There were also large increases in weak inhibitor use and no changes in overall
antidepressant use, suggesting shifts from stronger to weaker CYP2D6 inhibitors. By 2010,
strong CYP2D6 inhibitors were co-prescribed with tamoxifen in approximately 15% of
patients using antidepressants. These declines in strong CYP2D6 inhibitor co-prescribing
suggest that providers treating patients with breast cancer were responsive to information
regarding possible drug interaction risks.
Until recently, publications and guidelines encouraged providers to avoid strong inhibitors
in patients who were using tamoxifen. In our sample, we found that patients with previous
use of a strong inhibitor, more comorbidities, and a higher than average number of
outpatient visits were more likely to be co-prescribed a strong CYP2D6 inhibitor with
tamoxifen following the FDA advisory meeting.
Recent evidence raises questions about whether poor metabolizers of CYP2D6 have a higher
risk of disease recurrence [18, 19]. In fact, these studies add to a larger body of literature
that has produced contradictory data on the importance of CYP2D6 metabolism for patients
using tamoxifen.[20] Moreover, while these studies were based on large clinical trials and
were generally viewed as providing an overall answer to the debate regarding CYP2D6
Dusetzina et al. Page 6










metabolism and outcomes, [36] they have also received significant criticism.[37–39] Given
the currently mixed data regarding the impact of strong inhibitors on outcomes, the routine
use of antidepressants among breast cancer patients and the large number of treatment
alternatives available, the benefits of reducing co-prescribing of strong CYP2D6 inhibitors
and tamoxifen may outweigh any downsides.
When evaluating characteristics of patients who were co-prescribed antidepressants and
tamoxifen following the FDA Advisory Committee’s recommendation to change
tamoxifen’s label to warn of drug interaction risks, we observed that past strong inhibitor
use was associated with future use, and we also found that individuals with more comorbid
conditions and those using more outpatient care were more likely than others to be co-
prescribed a strong rather than a moderate or weak CYP2D6 inhibitor with tamoxifen. There
are several explanations that may account for this. Patients with more frequent office visits
and more comorbid illness may see multiple providers who prescribe different medications
and may not be aware of other prescribed therapies. Additionally, clinicians may hesitate to
change a patient’s medication prescribed by another specialist. Patients may also fail to
disclose information about their ongoing medication use to clinicians, impairing the
clinician’s ability to recognize a potential drug-drug interaction.
With regard to the impact of prior strong inhibitor use on later use, clinicians might have
hesitated to switch antidepressants for patients who were previously stabilized on a strong
inhibitor antidepressant. In fact, clinicians and patients must carefully weigh the benefits and
risks of changing therapies for patients who have responded well to a particular medication.
Given more recent evidence suggesting a lack of impact on CYP2D6 metabolism on
outcome, risks of switching for current antidepressant users may outweigh potential benefits.
It is important to note that clinicians who continued to prescribe strong inhibitors and
tamoxifen concurrently following the FDA advisory committee’s decision may have done so
for multiple reasons. For example, clinicians might have been unaware of, or disagreed with,
the data available at that time regarding potential interaction risk between tamoxifen and
CYP2D6 inhibitors. Additionally, they might have lacked information on medication
regimens currently used by the patient. These issues may be particularly relevant if primary
care providers or psychiatrists are managing a patients’ depression or anxiety, especially if
those providers do not share a medical record with the tamoxifen prescriber.
Because treatment-related side effects of endocrine therapies may impact adherence [40],
and untreated depression is associated with treatment non-adherence, poorer quality of life
and worse health outcomes for patients with cancer [27, 41, 42], it is important for patients
to continue to receive pharmacologic and non-pharmacologic therapies. For women
currently co-prescribed strong inhibitors and tamoxifen who remain concerned about a
potential drug interaction risk, there are many alternative treatments or treatment strategies
to consider. These include switching antidepressants (e.g., to weak inhibitors), switching to a
non-antidepressant treatment (e.g., to psychotherapy), or switching from tamoxifen to an
aromatase inhibitor (for post-menopausal women) if there are concerns that the patient
would experience adverse outcomes due to switching antidepressant therapies. As
mentioned previously, benefits and risks of therapeutic switching should be carefully
weighed by the patient and their provider.
When initiating therapy with antidepressants among women who are currently taking
tamoxifen, a prudent approach might be to avoid strong inhibitors as a first choice of
therapy. Although patients vary in their response to antidepressant treatments, these drugs
are similarly effective in treating depression or anxiety disorders [43, 44] and venlafaxine (a
weak inhibitor) may be effective in treating hot flashes among some breast cancer survivors
Dusetzina et al. Page 7










[45]. Moreover, among the known weak inhibitors, there are agents from each
antidepressant category and most are available in generic forms, suggesting that barriers to
initiating weak inhibitors over strong inhibitors (e.g., formulary restrictions, patient or
clinician preference for a specific category of antidepressants) are likely to be minimal.
This study has some limitations. First, we excluded women <50 years because including pre-
menopausal women would not allow for a well-matched control population. Furthermore,
we used age as an indicator of menopausal status but were unable to measure this directly,
so some women included may not have been candidates for aromatase inhibitors. Second,
using propensity score matched controls only accounts for measured confounders, thus
unmeasured confounders may still influence our results. Third, we lacked information on
antidepressant treatment preferences and reasons for treatment selection, including the
primary indication (e.g., depression, anxiety, or hot flashes). Fourth, our cohort included
women with employer-based insurance and/or supplemental Medicare coverage and our
results may not generalize to publicly insured (Medicaid or Medicare without employer
supplemental coverage) or uninsured individuals. Fifth, although we could identify the
specialty of physicians seen, we were unable to identify prescribing physicians. Sixth, new
data regarding management of hot flashes with medications such as venlafaxine (a weak
inhibitor) became available during our study period. This might account for some of the
increase in weak inhibitor use, particularly if there are large imbalances between tamoxifen
users and aromatase inhibitor users in the proportion receiving antidepressants for hot
flashes management. Seventh, we do not have information on patient genotype which might
have played a role in the decision to continue to use strong inhibitors among ongoing users.
Finally, declines in drug utilization are likely the result of a combination of factors including
media coverage, pharmaceutical promotion, regulatory actions and clinical communications.
While we use the FDA’s advisory committee meeting as reference point for our analysis,
this should not be construed to indicate that the committee’s recommendation was solely
responsible for the decline in co-prescribing observed in our study.
In conclusion, use of strong CYP2D6 inhibitors declined substantially among tamoxifen
users following dissemination of information suggesting a potential for increased risk with
co-prescribing. The evidence related to the impact of strong CYP2D6 inhibitors on breast
cancer recurrence remains controversial. Whether patients and providers will continue to
avoid strong inhibitor antidepressants is yet to be seen, but clinicians appear to be responsive
to drug interaction risk information in this setting.
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Figure 1. Proportion of Women Receiving Antidepressants and Endocrine Therapy by Month –
Propensity Score Matched Sample
The figure demonstrates the proportion of women taking tamoxifen (black line) and
aromatase inhibitors (gray line) who were also prescribed an antidepressant in each month of
observation.
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Figure 2. Antidepressant Co-Prescribing by CYP2D6 Status – Propensity Score Matched Sample
The figure demonstrates the proportion of medication fills for strong (black line), moderate
(gray line), and weak (light gray line) inhibitors among women taking tamoxifen (Panel 2a)
and aromatase inhibitors (Panel 2b).
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